Abstract
There is a large body of evidence that free radical-mediated oxidative damage is involved in the pathogenesis of neurodegenerative disease. Although it is unlikely that markers of such damage will have any diagnostic value, they might be of considerable interest in following disease progression and monitoring the efficacy of different treatments. Among such markers, there is evidence for the elevation of peripheral malondialdehyde levels in several neurodegenerative diseases, including Parkinson's disease, amyotrophic lateral sclerosis and Alzheimer's disease. The measurement of malondialdehyde levels, which is both simple and cheap to perform, can and should be incorporated into future clinical trials. This will allow a clearer picture to emerge as to whether malondialdehyde can be considered as a marker for the evolution of these diseases.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 22 November 2000, Received in revised form: 6 September 2001, Accepted: 11 September 2001
Rights and permissions
About this article
Cite this article
Dib, M., Garrel, C., Favier, A. et al. Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?. J Neurol 249, 367–374 (2002). https://doi.org/10.1007/s004150200025
Published:
Issue Date:
DOI: https://doi.org/10.1007/s004150200025